There is growing pressure from patients to make healthcare more transparent. However, there remain privacy concerns about publicizing clinical research data.
The FDA issued warning letters to several CBD companies for selling unapproved products with unsubstantiated medical claims.
Many have been assigned blame for the nation’s prescription opioid epidemic--including clinicians, patients, and pharmaceutical distributors. This has shifted attention away from policymaker attempts to address the crisis.
Not all products have to meet the U.S. Federal Drug Administration’s (FDA) approval: certain biologics and dietary supplements do not require it, and there are alternative pathways for OTC drugs and other products to skip the process.
Drugmakers have become increasingly entangled in kickback and bribery schemes, and as a consequence, face millions in settlement to the U.S. government.
The US Food and Drug Administration (FDA) has announced new restrictions concerning the marketing of tobacco products such as e-cigarettes and vape pens in an effort to mitigate risks to public health.